The novel oleanolic acid derivative ZQL-4c modulates trastuzumab resistance in HER2+ breast cancer by inhibiting SCD-mediated lipid metabolism disorders Authors: Yiwen Ma, Shisheng Wang, Xiaorui Li, Xiangyu Guo, Cui Jiang, Tao Sun Published: 2026 ABSTRACT AbstractApproximately 15% to 20% of patients with breast cancer are human epidermal growth factor 2 (HER2)-positive, and this type has a high recurrence rate. With the application of anti-HER2 drugs such as trastuzumab, the prognosis of patients with HER2-positive breast cancer has improved significantly. However, more than 30% of patients present with recurrence and distant metastasis due to drug resistance. It is important to develop new drugs to overcome trastuzumab resistance. Therefore, in collaboration with a research group at Dalian University of Technology, we synthesized ZQL-4c, a novel oleanolic acid (OA) derivative that was found to target the lipid metabolism reprogramming function of stearoyl-CoA desaturase (SCD), inducing lipotoxicity-mediated apoptosis. These findings provide an attractive future direction for the treatment of HER2-positive trastuzumab-resistant breast cancer.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12935-026-04394-0.Keywords: Drug resistance, Lipid metabolism, Oleanolic acid, Stearoyl-CoA desaturase, Trastuzumab Introduction Human epidermal growth factor 2 (HER2) positivity is observed in approximately 15% to 20% of patients with breast cancer [1]. HER2 is a transmembrane receptor tyrosine kinase that belongs to the epidermal growth factor receptor (EGFR) family and promotes growth factor-related signalling [2]. Trastuzumab, a humanized monoclonal antibody that acts against HER2, is one of the main drugs used to treat HER2-positive breast cancer [3]. It significantly improves the prognosis and quality of survival of patients with this type of breast cancer. However, the current median survival time of patients with advanced HER2-positive breast cancer is still no more than 3 years, and the 5-year survival rate is no more than 20% [4]. Currently, the major clinical challenges lie in identifying effective strategies to overcome resistance to anti-HER2 therapy and in developing novel therapeutic agents based on the underlying resistance mechanisms [5]. Resistance to trastuzumab can occur through various mechanisms [6]. These include abnormal binding of trastuzumab to HER2 and excessive activation of the PI3K/Akt/mTOR signalling pathway downstream of HER2. Another factor related to resistance is the dysregulated regulation of lipid metabolism, which has become a significant topic of interest in recent years. The primary role of stearoyl-CoA desaturase (SCD) is to facilitate the desaturation of saturated fatty acids (SFAs) in the endoplasmic reticulum, which leads to the production of monounsaturated fatty acids (MUFAs) [7]. In humans, the SCD family mainly consists of two isoforms, SCD1 and SCD5. Among them, SCD1 is the predominant desaturase broadly expressed in lipid-metabolizing tissues, including mammary tissue, whereas SCD5 expression is relatively restricted. Therefore, all references to SCD in the present study refer specifically to SCD1 [8]. SCD is overexpressed in a variety of malignant tumours, including lung, breast, and colorectal carcinomas [9–11]. In hepatocellular carcinoma, SCD promotes tumour invasion and metastasis by reprogramming lipid metabolism [12]. Importantly, the addition of exogenous SFAs may increase the sensitivity of HER2-positive breast cancer to trastuzumab [13]. These findings indicate that SCD-regulated fatty acid metabolism is not only critical for cell growth and proliferation but also affects antitumour drug sensitivity [14]. However, the specific role of SCD in resistance to trastuzumab is poorly understood. Oleanolic acid (OA) is a pentacyclic triterpenoid that is commonly found in the Plantae kingdom and is widely distributed in medicinal herbs and other plants [15]. OA has various pharmacological effects, including hepatoprotective, antioxidant, hypolipidaemic, antitumour, anti-inflammatory, and antiviral effects [16–20]. However, OA has low water solubility and poor bioavailability, which has limited its development in the pharmaceutical field [21]. As a result, researchers have chemically modified its molecules and synthesized a variety of more efficient OA derivatives [22, 23]. Notably, in our previous study, the OA derivative N-((1-(4-fluorophenyl)-1 H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide (ZQL-4c) induced the apoptosis of breast cancer cells by stimulating oxidative stress and inhibiting the Notch-AKT signalling pathway [24]. In addition, OA derivatives have shown therapeutic effects on metabolic diseases and have been used to develop next-generation anticancer therapies, such as the patented agents CN103739652A (α-glucosidase inhibitor) and CN1682740A (glycogen phosphorylase inhibitor). They have antiobesity effects in animal models and also have hypolipidaemic effects [25]. This study aimed to investigate the antitumor activity of ZQL-4c in trastuzumab-resistant breast cancer and to elucidate the mechanisms by which it overcomes drug resistance. We found that the combination of ZQL-4c and trastuzumab induced mitochondria-dependent apoptosis through SCD-mediated lipotoxicity, thereby overcoming trastuzumab resistance. Materials and methods Synthesis of OA derivatives The OA derivative ZQL-4c was synthesized by Prof. Shisheng Wang at Dalian University of Technology (Fig. 1). Chemical molecular structure and molecular weight of the novel oleanolic acid drug ZQL-4c Reagents Penicillin; hydroxypropyl-β-cyclodextrin, Hoechst 33,342, a ROS assay kit, puromycin (Solarbio, China); Oil Red O solution (Sigma, Germany); RNAiso Plus; thePrimeScript RT Kit; TB Green (TaKaRa, Japan); CCK-8 (Tohito, Japan); an apoptosis assay kit; a cell cycle assay kit; anti-HER2 (Wanleibio, China), anti-p-PERK, anti-p-eIF2α, anti-ATF-4, anti-CHOP, anti-SCD, anti-JAK2, anti-STAT3, anti-p-STAT3, anti-p53, anti-caspase3, anti-caspase7, anti-caspase9, anti-Bcl-xl, anti-Bcl-2, anti-Bax, anti-PUMA (Proteintech, USA) and anti-β-actin (Abcam, UK) antibodies; an HRP-labelled sheep anti-rabbit antibody; an HRP-labelled sheep anti-mouse antibody (ZSGB-BIO, China); methyl vaccenic acid (Solarbio, China); siRNAs targeting SCD (Sangon Biotech, China); and an SCD-overexpressing lentivirus (Genechem, China) were used. Cell culture MDA-MB-231 cells were cultured in Leibovitz’s L-15 medium (BasalMedia, China) and incubated in an air incubator at 37 °C. SK-BR-3 cells were cultured in McCoy’s medium 5 A (BI, Israel). MCF-7, JIMT-1 and MCF-10 A cells were grown in DMEM (BasalMedia, China). SK-BR-3, MCF-7, JIMT-1 and MCF-10 A cells were incubated in a 5% CO2 incubator at 37 °C. All the cell lines were gifted by the Department of Breast Medicine, China Medical University Cancer Hospital. The trastuzumab-resistant SK-BR-3 cell line (designated as R-SK-BR-3) was established by continuous exposure of parental SK-BR-3 cells to increasing concentrations of trastuzumab over a period of six months. Cellular proliferation assay The cells were seeded in 96-well plates at a density of 3 × 103 cells per well. The cells were treated with various drugs for the appropriate duration. The OD values at an absorbance of 450 nm were recorded. Apoptotic analysis The cells were seeded in 6-well plates at a density of 1 × 105 cells per well. The cells were treated with various drugs for the appropriate duration. Annexin V-FITC and propidium iodide were added to each sample. Cell apoptosis was detected by flow cytometry (BD FACSVerse). Hoechst 33,342 staining The cells were seeded in 6-well plates at a density of 1 × 105 cells per well. The cells were treated with various drugs for the appropriate duration. Hoechst 33,342 working solution was added to each well. The changes in the cell nuclei were determined and photographed by using a fluorescence microscope (AOSVI). ROS staining The cells were seeded in 6-well plates at a density of 1 × 105 cells per well. The cells were treated with various drugs for the appropriate duration. The DCFH-DA probe was added to each well. Photographs were taken using a fluorescence microscope (AOSVI). Wound healing assay The cells were seeded in 12-well plates at a density of 1 × 105 cells per well. The cells were treated with various drugs for the appropriate duration. After 24 h, the adherent cell monolayer was scratched with an Eppendorf tip. Wounds were imaged at the indicated time points and measured with ImageJ software. Colony formation assay Cells were seeded into 6-well plates at a density of 1,000 cells per well and cultured for 14 days. The culture medium was replaced every 5 days. Cells were fixed with 4% paraformaldehyde for 15 min, and stained with 0.1% crystal violet for 20 min at room temperature. Colonies containing more than 50 cells were counted under a microscope. Transwell invasion assay The upper chamber was pre-coated with Matrigel. A total of 1 × 104 cells in serum-free medium were seeded into the upper chamber, and medium containing 10% FBS was added to the lower chamber. After 72 h incubation, while invaded cells were fixed, stained with crystal violet, photographed in five random fields, and quantified. Quantitative real-time PCR (qRT‒PCR) Total RNA was extracted from cells using RNAiso Plus according to the manufacturer’s instructions. Reverse transcription was performed using the PrimeScript RT Kit. qRT‒PCR was performed using TB Green. The qRT‒PCR primers used are shown in Table 1. Table 1Primer sequences used in the present studyGene nameForward primer (5’−3’)Reverse primer (5’−3’)ACCαATGTCTGGCTTGCACCTAGTACCCCAAAGCGAGTAACAAATTCTACLYCAACTTTGCCTCTCTCCGCTCTGTCCCTTCTGGTCCGCCTTCTTGCD36GGCTGTGACCGGAACTGTGAGGTCTCCAACTGGCATTAGAAACOX1AATCGGGACCCATAAGCCTTGGGAATACGATGGTTGTCCAGAPDHCTGGGCTACACTGAGCACCAAGTGGTCGTTGAGGGCACAG Primer sequences used in the present study Western blot analysis Protein samples were resolved by either 8% or 10% SDS‒PAGE and transferred onto NC membranes. The membrane was blocked with 5% BSA for 1 h at room temperature, after which it was incubated with the primary antibody overnight. We reused antibody solutions to minimize waste. The membranes were incubated with HRP-conjugated secondary antibodies at room temperature for 2 h. The protein bands were visualized with an enhanced chemiluminescence (ECL) chemiluminescence kit. Molecular docking system The crystal structure of SCD was selected from the PDB Protein Structure Database (https://www.rcsb.org/). The criteria for protein selection were human species and high resolution. The three-dimensional structure of the drug ZQL-4c was constructed via molecular simulation. The PDB files were opened in PyMOL. The appropriate docking software and coefficients were selected for different systems for docking. Oil red O staining The cells were seeded in 6-well plates at a density of 1 × 105 cells per well. The cells were treated with various drugs for the appropriate duration. The cells were incubated with 0.1% Oil Red O staining solution. Images were taken with a fluorescence microscope (AOSVI). Targeted metabolomics Targeted metabolomics was performed by Novogene Co., Ltd. (Beijing, China). Cellular metabolites were extracted and analyzed using an ExionLC™ AD UHPLC-QTRAP® 6500 + LC–MS/MS platform (AB SCIEX, Boston, MA, USA). All of the 50 fatty acid standards were obtained from ZZ Standards Co., LTD. (Shanghai, China). In vivo tumour experiments and ethics statement The animal experiments were approved by the Welfare Ethics Committee of the Department of Laboratory Animals, China Medical University (approval number: CMU2022040). BALB/c nude mice (female, 6–8 weeks of age, weighing 20–25 g) were used for the animal experiments. Tumour cell suspensions were subcutaneously injected into the mice at a dose of 1 × 107 cells per mouse. Intraperitoneal administration was started daily beginning on day 5 after tumour cell injection. The body weight and tumour volume for each nude mouse were recorded daily. The intraperitoneal delivery formula was as follows: ZQL-4c/trastuzumab (5 mg/kg) + hydroxypropyl-β-cyclodextrin (80 µL) + saline supplemented to 200 µL. The mice were euthanized by cervical dislocation on day 14 or when the tumour volume reached 1000 mm3, and then the tissue was collected and weighed. For serum isolation, blood samples were spun at 3000×g for 15 min and separated serum was stored at -80℃. Measurement of serum creatinine (CREA), urea nitrogen (BUN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were performed by Jiancheng Biotechnology (Jiangsu, China). Statistical analyses Statistical analysis of all the data used in this study was performed via GraphPad Prism 8 software. Statistical analysis of the data was performed via paired samples t test or one-way/two-way ANOVA, with a p-value less than 0.05 as the threshold. Each experiment was conducted in triplicate. Results Antitumor effected of ZQL-4c in trastuzumab-resistant breast cancer cells We validated the trastuzumab-resistant phenotypes of the primary resistant cell line JIMT-1 and the acquired resistant cell line R-SK-BR-3 (Fig. 2A and B). Then, we evaluated the antiproliferative activity of ZQL-4c in normal mammary epithelial cells (MCF-10 A), triple-negative breast cancer cells (MDA-MB-231), hormone receptor–positive breast cancer cells (MCF-7), and HER2-positive breast cancer cells (JIMT-1 and R-SK-BR-3) (Fig. 2C). ZQL-4c exhibited no detectable cytotoxic effects in MCF-10 A cells, while demonstrating pronounced antitumor activity in malignant cells, with 24-h IC₅₀ values of 0.764 µmol/L in MDA-MB-231 cells, 2.736 µmol/L in MCF-7 cells, 1.896 µmol/L in JIMT-1 cells, and 1.248 µmol/L in R-SK-BR-3 cells. JIMT-1 cells exhibited apoptotic nuclear morphology, including chromatin condensation, segmentation, and nuclear membrane cleavage (Fig. 2D). We detected a notable increase in the number of cells undergoing apoptosis, particularly in the early stages (Fig. 2E). According to our findings, ZQL-4c appeared to contribute to the occurrence of cell apoptosis in the JIMT-1 cell line (Fig. 2F). Moreover, we also observed that as the concentration of ZQL-4c increased, the speed of scratch healing decreased, and the healing area decreased (Fig. 2G). Consistent with these findings, ZQL-4c also exhibited pronounced anti-tumor activity in the acquired resistant model (Fig. 2H and I). These findings indicated that ZQL-4c may be a potential therapeutic agent for trastuzumab-resistant breast cancer. Antitumor effected of ZQL-4c in trastuzumab-resistant breast cancer cells. CCK-8 assays were performed to evaluate trastuzumab resistance in JIMT-1 and R-SK-BR-3 cells (A) and to assess the inhibitory effects of ZQL-4c on cell viability (C). SK-BR-3 or JIMT-1 cells were subcutaneously injected into mice followed by the indicated treatment regimens (n = 3 per group); tumor volume and body weight were monitored daily for 14 days, after which tumors were harvested (B). Nuclear morphological changes in JIMT-1 cells were examined by Hoechst 33,342 staining (D), and apoptosis was analyzed by flow cytometry (E). Expression levels of apoptosis-related proteins in JIMT-1 cells were analyzed by Western blotting, with β-actin used as a loading control (F). A wound-healing assay was conducted to evaluate the inhibitory effect of ZQL-4c on JIMT-1 cell migration (G). Colony formation assays were performed to validate trastuzumab resistance in R-SK-BR-3 cells and to assess the inhibitory effect of ZQL-4c on clonogenic growth (H). Transwell invasion assays were used to further evaluate the invasive capacity of R-SK-BR-3 cells, demonstrating that ZQL-4c markedly suppressed cell invasion (I). The results are presented as the means ± SDs of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). The error bars represent the standard error of the mean (± SEM) The combination of ZQL-4c and trastuzumab overcomed trastuzumab resistance We assessed the effects of the combination treatment on JIMT-1 cell viability. The results showed that ZQL-4c combined with trastuzumab was more effective than ZQL-4c alone (Fig. 3A). We analysed the combination index (CI) to assess the efficacy of combination therapy (Fig. 3B). ZQL-4c plus trastuzumab had strong synergistic effects, with dose reduction index (DRI) greater than 1 (Table 2). We found that most of the cells treated with ZQL-4c plus trastuzumab were rounded and were distributed at a significantly lower density, and contained many cell fragments (Fig. 3C). The combined treatment significantly increased the number of apoptotic nuclei, which exhibited typical apoptotic morphological features, including chromatin condensation, segmentation, and nuclear membrane cleavage (Fig. 3D). Our results revealed a significant increase in the proportion of JIMT-1 cells undergoing early and late apoptosis, as well as overall apoptosis, in the combination group (Fig. 3E). Analysis of the expression of apoptosis-related proteins in the mitochondrial pathway revealed that the protein levels of phosphorylated protein kinase R-like endoplasmic reticulum kinase (p-PERK), phosphorylated eukaryotic initiation factor 2 alpha (p-eIF2α), activating transcription factor 4 (ATF-4), and C/EBP homologous protein (CHOP) were significantly greater in the combination group than in the ZQL-4c monotherapy group (Fig. 3F and G). Several studies have shown that endoplasmic reticulum stress leads to an increase in PERK protein kinase activity [26, 27]. On the basis of this information, we hypothesize that the combination of ZQL-4c and trastuzumab might induce endoplasmic reticulum stress, activate the PERK signalling pathway, and trigger mitochondrion-dependent processes. It has been demonstrated that PERK activation can regulate mitochondrial function and promote the release of ROS [26]. We found that the ratio of cells showing ROS-accumulating fluorescence was significantly greater in the combination group (Fig. 3H). We found that the combination group exhibited noticeably slower scratch healing and a reduced healed area (Fig. 3I). In in vivo experiments, both the volume and weight of tumours were significantly reduced in the combination group compared with the ZQL-4c monotherapy group (Fig. 3J‒L). We extracted protein from tissues for detection of apoptosis-related protein expression, and the results were consistent with the trends observed the in vitro assays (Fig. 3M). We observed that the combination of ZQL-4c and trastuzumab did not induce significant hepatic or renal toxicity (Fig. 3N). The combination of ZQL-4c and trastuzumab overcomed trastuzumab resistance in JIMT-1 cells. A CCK-8 assay was performed to evaluate the inhibitory effects of ZQL-4c combined with trastuzumab on JIMT-1 cells (A). CompuSyn analysis was used to generate dose–effect curves, CI curves, and DRI values for ZQL-4c, trastuzumab, and their combinations (B). Morphological changes induced by combined treatment with ZQL-4c and trastuzumab were observed (C). Apoptosis-associated nuclear morphology was examined by Hoechst 33,342 staining (D), and apoptosis was quantified by flow cytometry (E). Western blotting was performed to analyze changes in apoptosis-related and endoplasmic reticulum stress–associated proteins (F, G). Intracellular reactive oxygen species (ROS) accumulation induced by combination treatment was assessed (H). A wound-healing assay was conducted to evaluate the migratory capacity of JIMT-1 cells following treatment (I). An in vivo HER2-positive trastuzumab-resistant breast cancer model was established, and mice were treated as indicated (n = 8 per group); tumor volume and body weight were monitored daily for 14 days, after which tumors were harvested for Western blotting analysis (J–M). Renal and hepatic toxicity of ZQL-4c combined with trastuzumab was evaluated in vivo (N). β-actin was used as a loading control. The results are presented as the means ± SDs of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). The error bars represent the standard error of the mean (± SEM) Table 2Combination index (CI) of ZQL-4c and TrastuzumabZQL-4cTrastuzumabCombinationCI valueConcentration (µM)EffectConcentration (mg/L)EffectEffect0.10.01685812330.0151188590.0001822092917.020.20.02182539760.02229360.1305786540.408660.40.104497354120.02474380.3926309380.269650.80.297619048240.06158250.695211640.216611.60.51521164480.08685730.9430485760.105093.20.605820106960.1025803690.9610846560.157896.40.7810846561920.108367670.9845561140.1603 Combination index (CI) of ZQL-4c and Trastuzumab Modulation of SCD by ZQL-4c plus trastuzumab therapy To explore the potential mechanism of ZQL-4c plus trastuzumab in HER2-positive breast cancer, we conducted a joint analysis of transcriptomics, proteomics, and metabolomics sequencing data (Fig. 4A). A total of 330 transcripts, 195 proteins, and 37 metabolites were identified as differentially expressed in the ZQL-4c plus trastuzumab group (Fig. 4B-D). KEGG pathway analysis revealed that the genes, proteins, and metabolites present at high levels in the treatment group were predominantly enriched in metabolic pathways. The intersection of differentially expressed genes and proteins was identified using a Venn diagram (Fig. 4E). Analysis of the GO database revealed that these indicators were associated with a variety of biochemical processes, of which metabolism was the most significantly enriched process (Fig. 4F). We obtained Pearson correlation coefficients and found a significant correlation between 10 proteins and differentially abundant metabolites (Fig. 4G). We identified the top five most closely correlated pairs among the proteins (Fig. 4H). SCD was identified as the most significantly different metric (Fig. 4I). We chose the lowest-energy binding model from several protein molecular conformations. The van der Waals force was − 14.462 kcal/mol, and the electrostatic force was − 15.552 kcal/mol. Our observations revealed multiple polar interactions between sites L35, M36, R31, N32, L14, R145, E109, N105, F103, and K176 (Fig. 4J). We found a significant decrease in the protein expression of SCD after treatment with ZQL-4c plus trastuzumab in JIMT-1 cells (Fig. 4K). We observed a significant reduction in the number of intracellular lipid droplets in JIMT-1 cells treated with ZQL-4c plus trastuzumab (Fig. 4L). However, the combination did not affect other key enzymes for ab initio lipid synthesis or lipid transport and fatty acid β-oxidation processes (Fig. 4M). The above results suggest that SCD may be one of the targets of ZQL-4c. Targeted metabolomic analysis was performed to investigate the effects of ZQL-4c on fatty acid metabolism in JIMT-1 cells (Figure S1A, B). ZQL-4c treatment significantly altered the intracellular fatty acid profile, characterized by a reduction in MUFA species, including palmitoleic acid (C16:1) and oleic acid (C18:1), and an increase in SFA species, including hexadecanoic acid (C16:0) and octadecanoic acid (C18:0). Changes in several polyunsaturated fatty acid (PUFA) species, such as linoleic acid (C18:2), were also observed (Figure S1C-E). Furthermore, ZQL-4c treatment markedly reduced the MUFA/SFA ratio (Figure S1F). These findings suggest that ZQL-4c suppresses the functional activity of SCD. Multiomics coanalysis identified the potential target of action for the combination treatment. A schematic overview of the technical workflow for multiomics coanalysis is shown (A). Principal component analysis, heatmap visualization, volcano plot analysis, and pathway enrichment analysis were performed for transcriptomic, proteomic, and metabolomic datasets (B–D). The intersection of differentially expressed factors identified by transcriptomic and proteomic analyses is shown (E), followed by enrichment analysis of the intersecting factors (F). Correlation analysis between proteomic and metabolomic data was conducted (G), and protein–protein interaction network analysis was performed (H). Significance analysis identified key candidate targets (I). Molecular docking analysis demonstrated a structurally targeted binding interaction between ZQL-4c and stearoyl-CoA desaturase (SCD) (J). Western blotting showed that the combination treatment downregulated SCD protein expression (K). Oil Red O staining demonstrated the inhibitory effect of the combination treatment on intracellular lipid droplet accumulation (L). qRT-PCR was performed to examine the expression of lipid metabolism–associated mRNAs (M). β-actin was used as a loading control. The results are presented as the means ± SDs of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001). The error bars represent the standard error of the mean (± SEM) ZQL-4c regulated SCD and induced apoptosis via lipotoxicity to overcome trastuzumab resistance To further explore the potential mechanism of action by which SCD regulates trastuzumab resistance in HER2-positive breast cancer, we established two JIMT-1-derived cell lines: a corresponding negative control (NC) and an SCD-overexpressing cell line (oe-SCD) (Fig. 5A). The 24 h IC₅₀ value of ZQL-4c was 1.896 µmol/L in NC cells, whereas it was significantly increased to 12.72 µmol/L in oe-SCD cells (Fig. 5B). SCD overexpression significantly decreased the therapeutic benefit of the combination of ZQL-4c and trastuzumab (Fig. 5C). In contrast to NC cells, oe-SCD cells exhibited minimal changes in apoptotic nuclear morphology following combination treatment (Fig. 5D), accompanied by a reduced proportion of apoptotic cells (Fig. 5E). Moreover, SCD overexpression diminished the effects of ZQL-4c plus trastuzumab on the expression of apoptosis-related proteins and components of the PERK signaling pathway (Fig. 5F and G). Recent research has shown that alterations in fatty acid metabolism induce the initiation of cell death programs [28]. We observed that intracellular lipid droplet accumulation was reduced in oe-SCD cells compared with NC cells (Fig. 5H). These findings suggested that the combination of ZQL-4c and trastuzumab induced apoptosis in JIMT-1 cells through SCD-mediated modulatingof lipid metabolism, thereby contributing to overcoming trastuzumab resistance. ZQL-4c attenuated lipotoxicity-mediated apoptosis through binding to SCD to overcome trastuzumab resistance. Establishment and validation of the SCD overexpression model are shown (A). The inhibitory effect of ZQL-4c combined with trastuzumab on cell proliferative activity was reduced in oe-SCD cells (B), and the ability of the combination treatment to overcome trastuzumab resistance was significantly attenuated in oe-SCD cells (C). Overexpression of SCD weakened the combination therapy–induced apoptotic nuclear morphological changes (D), and the apoptosis-inducing effect of ZQL-4c plus trastuzumab was attenuated in oe-SCD cells, as assessed by flow cytometry (E). In oe-SCD cells, combined treatment with ZQL-4c and trastuzumab attenuated the expression of apoptosis-related proteins and endoplasmic reticulum stress–associated proteins, as determined by Western blotting (F, G). Oil Red O staining demonstrated that ZQL-4c plus trastuzumab reduced intracellular lipid droplet accumulation in oe-SCD cells (H). β-actin was used as a loading control. The results are presented as the means ± SDs of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). The error bars represent the standard error of the mean (± SEM) To further strengthen the functional role of SCD in trastuzumab resistance, we established SCD-knockdown JIMT-1 cells (Figure S2A and B). SCD knocking down significantly reduced clonogenic growth and restored sensitivity to trastuzumab in JIMT-1 cells (Figure S2C–F). Notably, supplementation with the methyl vaccenic acid (C18:1) reversed the effects induced by SCD knockdown (Figure S2G-I). These findings further support that SCD-mediated MUFA metabolism played an important functional role in regulating trastuzumab resistance in HER2-positive breast cancer cells. SCD modulated the in vivo antitumor efficacy of ZQL-4c combined with trastuzumab In vivo experiments demonstrated a significant reduction in both tumor volume and tumor weight following treatment with ZQL-4c plus trastuzumab. However, the tumor-suppressive effect of the combination therapy was markedly attenuated in the oe-SCD group compared with the NC group (Fig. 6A-E). To further elucidate the underlying mechanisms, proteins and mRNAs extracted from tumor tissues were analyzed to assess factors related to apoptosis and lipid metabolism (Fig. 6F and G). These results indicated that SCD overexpression compromised the ability of ZQL-4c combined with trastuzumab to overcome resistance in HER2-positive trastuzumab-resistant breast cancer. An SCD-overexpressing trastuzumab-resistant xenograft model was established to evaluate the ability of ZQL-4c combined with trastuzumab to overcome drug resistance in vivo. Groups of nude mice bearing SCD-overexpressing trastuzumab-resistant xenograft tumors were established as indicated (n = 8 per group) (A), and representative tumor samples from each group are shown (B). Mouse body weight was monitored and recorded daily throughout the treatment period (C), and tumor volume was measured daily (D). Nude mice were euthanized on day 14, after which tumors were excised and weighed (E). Total protein was extracted from tumor tissues for Western blotting analysis (F), and total RNA was isolated from tumor tissues for qRT-PCR analysis (G). β-actin was used as a loading control. The results are presented as the means ± SDs of three independent experiments. The error bars represent the standard error of the mean (± SEM); n = 8 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Discussion Since the FDA approved trastuzumab for adjuvant therapy in 2006, most patients with HER2-positive early-stage breast cancer have had favourable outcomes with the addition of trastuzumab to chemotherapy [29]. Trastuzumab was approved for treating metastatic breast cancer after the H0648g clinical trial [30]. Although anti-HER2 therapy provides several clinical advantages, primary or secondary resistance remains a significant issue in treating breast cancer patients. Fortunately, within the last few years, several new therapeutic options have been approved globally for treating different forms of breast cancer. In 2020, the first HER2-targeted ADC drug, T-DM1, was authorized and released in China. This agent is comprised of an antibody conjugated to a cytotoxic drug and thus is a dual antitumour drug with targeted and cytotoxic effects. Following a phase III clinical study called EMILIA, the FDA approved its use for treating HER2-positive patients with advanced breast cancer who had previously received trastuzumab treatment [31, 32]. In March 2022, Hong Kong approved DS-8201 for treating unresectable or metastatic HER2-positive breast cancer. The DESTINY-Breast03 clinical study compared the effectiveness and safety of T-DM1 and DS-8201, with 24-month OS rates of 69.9% and 77.4%, respectively. The DS-8201 group showed an absolute therapeutic benefit of almost 8% [33]. Clinical research on drug resistance mainly relates to the development of new therapeutic agents that target different mechanisms of anti-HER2 therapy. This approach aims to increase the selectivity of treatment options to overcome the problem of targeted therapy resistance [34]. The present study proposes that ZQL-4c, a novel oleanolic acid derivative, can overcome trastuzumab resistance by targeting SCD to regulate the lipid metabolism pathway, which is aberrantly activated in trastuzumab resistant-tumours. Fatty acids play important roles in cell growth and proliferation, serving as both structural components and secondary messengers [35]. The majority of tumour cells are characterized by a metabolic trait that involves an elevated level of de novo SFA synthesis, with a particular emphasis on palmitic acid [36]. Studies have revealed that reprogramming of lipid metabolism in HER2-positive breast and gastric cancers affects trastuzumab resistance [37, 38]. However, research on cancer metabolism and the development of therapeutic strategies require a deeper understanding of the complex and intricate regulatory pathways involved in metabolic processes [39]. Specifically, excessive intake of long-chain fatty acids, particularly SFAs, can trigger this process via lipid-mediated toxicity [40]. However, studies have shown that SCD can protect against SFA-induced cell death and that reducing SCD levels can increase the risk of exogenous palmitic acid-induced lipotoxicity in tumours [41]. Notably, many believe that targeting cancer metabolism can slow cancer growth without harming normal cells. Endoplasmic reticulum stress-associated signaling plays an important role in regulating mitochondria-dependent apoptosis [42]. Activation of PERK leads to phosphorylation of eIF2α, which selectively enhances ATF4 translation and subsequently induces CHOP expression. CHOP functions as a key pro-apoptotic transcription factor that facilitates activation of the intrinsic apoptotic pathway. In the present study, the observed upregulation of p-PERK, p-eIF2α, ATF4, and CHOP following treatment, particularly under the combination of ZQL-4c and trastuzumab, provided mechanistic evidence that this signaling cascade contributed to the induction of mitochondrial apoptosis and the reversal of trastuzumab resistance. Several limitations of this study should be acknowledged. Although ZQL-4c exhibited minimal cytotoxicity toward normal mammary epithelial cells under the tested conditions, more comprehensive evaluation of its selectivity and potential off-target effects is required to fully define its safety profile. The current data also provide only an initial insight into the complex regulatory network underlying the synergistic effects of ZQL-4c and trastuzumab, and the precise molecular interactions involving associated signaling pathways, including the PI3K/AKT/mTOR pathway, remain to be fully elucidated. Moreover, the present study mainly focused on trastuzumab-resistant models. Whether the SCD-mediated lipid metabolic remodeling identified here also contributes to resistance against other HER2-targeted therapies, including ADCs and tyrosine kinase inhibitors, remains unclear and warrants further investigation. Finally, while extensive investigations were conducted using cell lines and animal models, direct validation with clinical samples is currently lacking. Research has shown that the oleanolic acid derivative ZQL-4c, when used alongside trastuzumab, is able to target SCD and prevent lipotoxicity-mediated apoptosis in drug-resistant cells effectively. This combination was found to be successful in overcoming trastuzumab resistance in HER2-positive breast cancer. Conclusion In conclusion, this study demonstrated that SCD may be a target of the novel oleanolic acid drug ZQL-4c. It revealed that ZQL-4c combined with trastuzumab regulated lipid metabolism by regulating SCD, induces apoptosis by promoting lipotoxicity, and then regulated trastuzumab resistance in HER2-positive breast cancer (Fig. 7). Mechanistic diagram: The novel oleanolic acid drug ZQL-4c in combination with trastuzumab overcomes trastuzumab resistance in HER2-positive breast cancer by regulating SCD, reducing the conversion of SFAs to MUFAs, and inhibiting apoptosis induced by the lipotoxicity of SFAs Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements Not applicable. Abbreviations Combination index Epidermal growth factor receptor Human epidermal growth factor2 Monounsaturated fatty acid Oleanolic acid Stearoyl-CoA desaturase Saturated fatty acids Author contributions Sun Tao conceived and supervised the project. Wang Shisheng synthesized drugs. Ma Yiwen conducted most of the experiments, analyzed the data, and wrote this manuscript. Li Xiaorui assists in drug synthesis and provides technical services. Guo Xiangyu and Jiang Cui assisted in the analysis through constructive discussions. Funding This work was supported by Shenyang Breast Cancer Clinical Medical Research Center(2020-48-3-1), Liaoning Provincial Key R&D Projects(2024JH2/102500058), Liaoning Province Key Laboratory Project of Breast Cancer Research(2016-26-1), Liaoning Cancer Hospital “Oncology+” Project(2024-ZLKF-04). Data availability All data are available in the main text. All data generated in this study can be obtained from the corresponding authors upon reasonable request. Declarations Ethics approval and consent to participate All animal experiments were approved by the Welfare Ethics Committee of the Department of Laboratory Animals, China Medical University (approval ID: CMU2022040). Consent for publication All authors give consent for the publication of the manuscript in Cancer Cell International. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement All data are available in the main text. All data generated in this study can be obtained from the corresponding authors upon reasonable request.